SCS AUA 2025 Bladder Cancer

Viewing 1-13 of 13 articles

SCS AUA 2025: Underreporting of CIS in Patients with High-Grade Papillary NMIBC

SCS AUA 2025: Novel Therapeutic Regimens in Previously Untreated Metastatic Urothelial Carcinoma: A Systematic Review and Bayesian Network Meta-Analysis

SCS AUA 2025: Penelope: Tissue Penetration of Gemcitabine Phosphate Metabolites Following TAR-200 Administration Versus Standard Intravesical Instillation in Minipigs

SCS AUA 2025: Trials in Progress: BOND-003 Cohort P: A Multi-Institutional, Single-Arm Study of Intravesical Cretostimogene Grenadenorepvec for Treatment of High-Risk, Papillary Only, BCG-Unresponsive NMIBC

SCS AUA 2025: Trial in Progress: PIVOT-006 – a Phase 3, Randomized Study of Adjuvant Intravesical Cretostimogene Grenadenorepvec Versus Surveillance for the Treatment of Intermediate Risk NMIBC

SCS AUA 2025: Updates to the CORE-008 Trial Protocol: A Phase 2 Multi-Arm, Multi-Cohort Study to Evaluate Intravesical Cretostimogene Grenadenorepvec in Patients with High-Risk NMIBC

SCS AUA 2025: Streamlined, Patient-Centric Design of the Cretostimogene Grenadenorepvec Expanded Access Program in Patients with NMIBC Unresponsive to BCG

SCS AUA 2025: Preliminary Results from LEGEND: A Phase 2 Study of Detalimogene Voraplasmid, a Novel, Investigational, Non-Viral Genetic Medicine for High-Risk NMIBC

SCS AUA 2025: Piloting a Web-Based Urinary Diversion Decision Aid

SCS AUA 2025: TAR-200 Monotherapy in Patients with BCG-Unresponsive High-Risk NMIBC CIS: 1-Year Durability and Patient Reported Outcomes from SunRISe-1

SCS AUA 2025: Association Between Prior Pelvic Radiotherapy and Surgical Outcomes of Radical Cystectomy for Bladder Cancer: Analysis of National Surgical Quality Improvement Program Targeted Cystectomy Database

SCS AUA 2025: Keynote Lecture: Clinical Management of NMIBC

SCS AUA 2025: Enrollment Characteristics of Underrepresented Patients in Clinical Trials Using Cretostimogene Grenadenorepvec for High Risk BCG-Unresponsive NMIBC